Introduction {#Sec1}
============

Following the path of holistic medicine, on the footsteps of Hippocrates, who encouraged his disciples to focus their attention more on "what kind of person has a disease than to know what kind of disease a person has" \[[@CR1]\], the human being has reached the goal of a molecular knowledge of itself, revealing the secrets of the genome, through the Human Genome Project completed in 2003. The last decades have seen enormous advances in proteomics, metabolomics and genomics, but the path to the summit is still long \[[@CR2]\], as well illustrated by the complexity of the microbiome \[[@CR3]\].

From the current stratified medicine, which identifies a group of patients who can benefit from a treatment, medicine is moving toward a personalized approach, whose goal is the right therapy for the right patient at the right time: in other words, a medicine that takes into account individual variability to realize the best preventive and therapeutic strategies \[[@CR4]\]. Therapeutic resources for rheumatologic disorders have had a significant development with the advent of biotechnological therapies which have radically changed the course of the disease, the prognosis and the patient's quality of life. These concepts require a personalized approach based on the risk stratification and on the genetic background of the patient, as well illustrated by Talamonti and colleagues in the case of HLA-Cw06 to predict the response to ustekinumab \[[@CR5]\]. Despite these improvements, not all autoimmune diseases respond adequately to therapeutic agents nor we can predict which patients are more susceptible; therefore, it is important to focus on specific preventive measures to identify the ones at risk of developing autoimmune diseases and those who may lead to more severe manifestations.

To realize the purpose of personalized medicine in rheumatology, one of the most useful examples of biomarkers capable of identifying and predicting the outcome of patients, to set appropriate preventative measures, is representing by serum autoantibodies.

Personalized medicine {#Sec2}
=====================

Personalized medicine is a system that integrates molecular and biochemical characteristics with patient clinical data, thus introducing the possibility of predicting the disease before the onset of clinical signs and symptoms. It also offers the opportunity to focus on prevention and early intervention, rather than treating advanced stages of diseases and their complications. In this perspective, medical care has to be tailored for each individual, with the aim of offering the best available care for each patient \[[@CR6], [@CR7]\].

This approach is part of the "P4" medicine, which not only recognizes the personalized nature of modern medicine, but also expands its horizon to its predictive, preventive and participatory identity \[[@CR8]\]. There are numerous advantages in personalizing our medical approach to patients rather than disease, and one of these is the first "P", that is, prediction. Personalized medicine is expected to subdivide patients into high- and low-risk tiers, based on the integration between genetic factors and biomarkers that provide information on the severity and progression of the diseases \[[@CR9], [@CR10]\]. These aspects need to be combined with other factors to increase their predictive value; these include lifestyle (i.e., smoking, obesity), family history for autoimmune disease, genetic profile, clinical manifestation and other laboratory parameters; all of these should be considered as a potential target for prevention and delaying the onset and progression of disease, possibly mediated by additional mechanisms such as the microbiome or epigenetic changes \[[@CR9], [@CR11]\]. In this scenario, serum autoantibodies are potentially helpful markers to recognize variants of the same syndrome, enabling to subdivide patients into categories to predict the course of the disease and the possible response to treatment. By excluding patients for whom diagnostic and therapeutic measures are unnecessary, superfluous waste of resources is prevented, resulting in benefits both for the patient and the health-care system \[[@CR6], [@CR12]\].

The second "P" stands for prevention, whose purpose is to identify at-risk individuals before the development of clinical manifestations, to implement preventive measures \[[@CR13]\]. Traditionally, therapeutic decisions were taken on the basis of physical signs and symptoms observed during medical examination, but frequently these features failed to fully describe diseases. In fact, these signs are often non-specific and subjective; they are also often blurred or absent at the initial stages. So, this approach may miss the opportunity for prevention and early intervention, which is fundamental for the outcome of the patient \[[@CR6]\]. Different from this approach, the purpose of personalized medicine is to use biomarkers as screening to identify subjects at high risk of developing disease. This can lead to clinical and economic benefits that come from the prevention of late diagnosis and treatment of complications, resulting in reduced hospitalization for adverse drug reactions and less unnecessary diagnostic interventions. It is not to be underestimated, however, that with the improvement of the quality of life, patients are less likely to use drugs and they would address less frequently to the clinician \[[@CR9], [@CR12]\].

The third "P" is to personalize. "Happy families are all alike; every unhappy family is unhappy in its own way"; paraphrasing this Tolstoy's quote, when people have a problem, they feel different from the others and feel that they do not belong to the average cohort. As a matter of fact, that is not only a subjective perception, but indeed every individual, like the same diseases, are unique, from the genome to environmental factors \[[@CR14]\]. In addition, the interpersonal diversity influences the therapeutic response \[[@CR13]\]. This variability is elegantly illustrated by monozygotic twins that are largely discordant for autoimmune and chronic inflammatory conditions, thus possibly underlining the effects of non-hereditary factors \[[@CR15]\]; hence, each person must be treated as a unique individual \[[@CR16]\]. Based on this assumption, pharmaceutical research is shifting from mass therapies to targeted therapies, according to biomarkers that identify those patients who are more likely to successfully respond to treatments \[[@CR17]\].

Finally, the fourth "P" indicates the participatory role of personalized medicine; the individual must be involved in the preventive process and personalized treatment to be successful \[[@CR18]\]. This main role covered by the individual enriches the model of patient-centered medicine.

We should be aware that autoantibodies represent only a piece (with reasonable costs and within reach for all clinical settings) of a larger scenario and it is obviously unlikely that they are sufficient to achieve personalized medicine.

The ABC of serum autoantibodies {#Sec3}
===============================

Autoimmune diseases are estimated to affect nearly 5% of the US population \[[@CR19]\] and in the vast majority of cases these are characterized by serum autoantibodies which represent diagnostic markers with, in some cases, a prognostic value and thus in agreement with a personalized management \[[@CR11], [@CR20]\], as in the case of paraneoplastic autoimmunity \[[@CR11]\]. In general terms, the autoantibody development more frequently precedes the clinical onset of disease \[[@CR11], [@CR20], [@CR21]\]. Specific antibody profiles can lead to the identification of disease sub-phenotypes, but only in a few cases the antibody titer correlates with the severity of clinical manifestations or the response to treatment. Therefore, autoantibodies may help the clinician in determining the follow-up and in choosing an appropriate therapy, but might be ineffective in disease severity monitoring \[[@CR11], [@CR20], [@CR21]\].

The inconvenient truth of autoantibodies is that these are also detected in a substantial percentage of healthy subjects; thus, their isolated finding has a low positive predictive value which needs to be integrated with other laboratory parameters and patient risk factors \[[@CR22]\]. So, it is true that early diagnosis can reduce the economic burden of health care, but the interpretation of serum autoantibodies must be done with proper judgment to avoid inappropriate diagnosis and superfluous treatments. Instead, in subjects with high pre-test probability of an autoimmune disease, the autoantibody positivity is sufficient to set preventative measures such as the elimination of modifiable proposed or established risk factors (smoking, obesity and UV exposure among others) \[[@CR11]\] and to warrant a regular rheumatological follow-up.

Antinuclear antibodies (ANA) {#Sec4}
----------------------------

ANA are the most frequently (and often inappropriately) prescribed autoantibody test and they are virtually always positive in connective tissue diseases, i.e., systemic lupus erythematosus (SLE), Sjögren's syndrome (SjS), scleroderma (SSc), polymyositis and dermatomyositis (PM/DM). The ANA interpretation must thus be driven by clinical suspicion, but their interpretation also depends on both titer and pattern. Different staining patterns, classified into three major groups, nuclear, cytoplasmic and mitotic, give indication on the significance of ANA and type of rheumatic disease (Table [1](#Tab1){ref-type="table"}), and the recent work from the autoantibody standardization group (<http://www.ANApatterns.org>) provided a long overdue description of the possible profiles. In fact, the gold standard for detecting ANA remains indirect immunofluorescence test (IIF) on HEp-2 cells; however, IIF is time consuming and requires skilled operators to avoid variability. So, new ANA testing strategies have emerged in the last decades, particularly in terms of automation and multiplex analyses. The expected advantages of automated IIF are the reduction of false-negative and false-positive results, the improvement of the uniformity between different readers and laboratories and the efficiency of the evaluation procedure \[[@CR23]\]; but unfortunately the sensitivity for rare patterns is not yet adequate and can lead to false-negative results \[[@CR24], [@CR25]\].Table 1IIF ANA patterns and relevant clinical associationsPatternRelated antigensRelated diagnosisNuclear HomogeneousdsDNA, histones, nucleosomesSLE, drug-induced lupus, JIA SpeckledhnRNP, U1RNP, Sm, SS-A, SS-B, RNAP-III, Mi-2, KuMCTD, SLE, SjS, DM, SSc/PM overlap  Dense fine speckledDFS70/LEDGFRare in SLE, SjS, SSc  Fine speckledSS-A, SS-B, Mi-2, TIF1γ, TIF1β, Ku, RNA helicase A, replication protein ASjS, SLE, DM, SSc/PM overlap  Large/coarse speckledhnRNP, U1RNP, Sm, RNAP-IIIMCTD, SLE, SSc CentromereCENP-A/BlcSSc, PBC Discrete nuclear dots  Multiple nuclear dotsSp100, PML protein, MJ/NXP-2PBC, SARD, PM/DM  Few nuclear dotsp80-coilin, SMNSjS, SLE, SSc, PM, asymptomatic subjects Nucleolar  HomogeneousPM/Scl75, PM/Scl100, Th/To, B23 nucleophosmin, nucleolin, No55/SC65SSc, SSc/PM overlap  ClumpyU3-snoRNP/fibrillarinSSc  PunctateRNAP-I, hUBF/NOR-90SSc, SjS Nuclear envelope (NE)  Smooth NELamins A, B, C, or lamin associated proteinsSLE, SjS, seronegative arthritis  Punctate NENuclear pore complex proteinsPBC Pleomorphic  PCNA-likePCNASLE, other conditions  CENP F-likeCENP-FCancer, other conditionsCytoplasmic Fibrillar  Linear/actinActin, non-muscle myosinMCTD, CH, cirrhosis, MG, CD, PBC, long-term HD  Filamentous/microtubulesVimentin, cytokeratinInfections or inflammations, long-term HD, ALD, SARD, PsO, healthy subjects  Segmentalα actinin, vinculin, tropomyosinMG, CD, UC Speckled  Discrete dotsGW182, Su/Ago2, Ge-1PBC, SARD, neurological and autoimmune conditions  Dense fine speckledPL-7, PL-12, ribosomal P proteinsASS, PM/DM, SLE, juvenile SLE, neuroSLE  Fine speckledJo1/histidyl-tRNA synthetaseASS, PM/DM, lcSSc, IPE Reticular/AMAPDC-E2/M2, BCOADC-E2, OGDC-E2, E1α subunit of PDC, E3BP/proteinXPBC, SSc, rare in other SARD Polar/Golgi-likeGiantin/macrogolgin, golgin-95/GM130, golgin-160, golgin-97, golgin-245Rare in SjS, SLE, RA, MCTD, GPA, ICA, PCD, viral infections Rods and ringsIMPDH2, othersHCV patients post IFN/ribavirin, rare in SLE,\
Hashimoto's and healthy controlsMitotic CentrosomePericentrin, ninein, Cep250, Cep110, enolaseRare in SSc, RD, infections (viral and mycoplasma) Spindle fibersHsEg5Rare in SjS, SLE, other SARD  NuMA-likeCentrophilinSjS, SLE, other Intercellular bridgeAurora kinase B, CENP-E, MSA2, KIF14, MKLP1Rare in SSc, RD, malignancies Mitotic chromosomal envelopeModified histone H3, MCA1Rare in DLE, CLL, SjS, PMRTable [1](#Tab1){ref-type="table"} illustrates ANA patterns in IIF in three major categories, subdivided into groups and subgroups of patterns, with their antigenic and diagnostic associations. The information was taken from <http://www.ANApattern.org> and the related diagnoses were added by Chan EKL et al. \[84\]*SLE* systemic lupus erythematosus, *JIA* juvenile idiopathic arthritis, *MCTD* mixed connective tissue disease, *SjS* Sjögren's syndrome, *DM* dermatomyositis, *PM* polymyositis, *SSc* systemic sclerosis (*lc* limited, *dc* diffuse), *PBC* primary biliary cholangitis, *SARD* systemic autoimmune rheumatic diseases, *CH* chronic hepatitis, *MG* myasthenia gravis, *CD* Crohn's disease, *HD* haemodialysis, *ALD* alcoholic liver disease, *PsO* psoriasis, *UC* ulcerative colitis, *ASS* anti-synthetase syndrome, *IPE* idiopathic pleural effusion, *RA* rheumatoid arthritis, *GPA* granulomatosis with polyangiitis, *ICA* idiopathic cerebellar ataxia, *PCD* paraneoplastic cerebellar degeneration, *RD* Raynaud's phenomenon, *DLE* discoid lupus erythematosus, *CLL* chronic lymphocytic leukaemia, *PMR* polymyalgia rheumatica

It is still unclear what significance ANA may have in asymptomatic patients, since they are not specific markers of connective tissue diseases and can be falsely positive in healthy subjects (the prevalence of ANA in the general population is 13.8%) \[[@CR26]\], especially in seniors, as well as in patients with other chronic inflammatory or infectious diseases; otherwise, they can precede clinical manifestations and diagnosis in SSc \[[@CR27]\] and SLE \[[@CR28]\]. The current recommendations state that ANA-positive subjects should be tested for antibodies to extractable nuclear antigens (anti-ENA) and anti-double-stranded DNA antibodies (anti-dsDNA) \[[@CR29], [@CR30]\]. The presence of multiple antibodies thus becomes specific for systemic rheumatic disorder and helps the diagnostic process. To improve the appropriateness of the immunological diagnosis of systemic autoimmune diseases, to accelerate time for completing diagnostic process and to avoid waste of money, the introduction of ANA reflex test has been proposed \[[@CR31]\]. The diagnostic algorithm suggested by Tonutti and colleagues begins with a first-line high sensitivity test (i.e., ANA IIF on HEp-2 cells) to allow antibody positivity recognition and the definition of pattern and titer. The second-line tests (high specificity) are done for ANA titers ≥1:160 and include, as mentioned, anti-dsDNA and anti-ENA (by ELISA) to evaluate specific antigenic expression. Figure [1](#Fig1){ref-type="fig"} shows the second-line tests based on the ANA patterns found in IIF.Fig. 1ANA reflex test, modified from Tonutti et al. \[[@CR31]\]

The predictive significance of ANA has been clearly demonstrated in the seminal work by Arbuckle and colleagues \[[@CR28]\]. They studied 130 patients with SLE, whose serum had been collected many years before the diagnosis. Most patients harbored at least one autoantibody up to 9 years before the development of clinical manifestations and therefore diagnosis of SLE, in particular ANA and also antiphospholipid, anti-Ro and anti-La antibodies \[[@CR32]\]. The mean time to diagnosis for these autoantibodies was about 3.4 years, while for anti-double-stranded DNA autoantibodies 2.2 years. Later predictors of disease were anti-Sm and anti-nuclear ribonucleoprotein antibodies, which tended to coincide with the onset of signs and symptoms. Another interesting observation is that new types of autoantibodies gradually accumulated before the diagnosis and reached a plateau at the diagnosis. Considering that while ANA, anti-Ro, anti-La and anti-phospholipid antibodies may also be present in healthy subjects, anti-dsDNA, anti-Sm and anti-nuclear ribonucleoprotein antibodies are very rare in the general population. Accordingly, the positivity of these aforementioned autoantibodies should lead to close monitoring.

The value of ANA is not limited to diagnosis, but may have a prognostic role in specific clinical settings such as SSc, where the nucleolar pattern has been associated with a more rapid progression to late scleroderma pattern at nailfold capillaroscopy \[[@CR33]\]. Moreover, the presence of abnormal nailfold capillaries with ANA positivity is associated with an increase of mortality in patients with Raynaud's phenomenon without previously known connective tissue disease exclusively in women \[[@CR34]\]. The ANA prognostic value is also reported in juvenile idiopathic arthritis, being associated with the predisposition to uveitis \[[@CR35]\].

Finally, ANA and anti-ENA, in particular anti-Scl-70 antibodies, may be associated with malignancies, especially in patients with SSc and inflammatory myositis \[[@CR36]\]. Another correlation has been reported with lymphomas, as serum ANA were significantly higher in patients with disease than in controls. In addition, it has been found that the level of lactate dehydrogenase in ANA-positive patients was lower, thus suggesting that these patients have a better prognosis than ANA-negative patients, probably demonstrating the existence of an anti-tumor response that can be associated with a better prognosis \[[@CR37]\].

Anti-citrullinated peptide antibodies (ACPA) {#Sec5}
--------------------------------------------

ACPA, together with rheumatoid factor (RF), are the characteristic antibodies of rheumatoid arthritis (RA), manifesting higher specificity and lower sensitivity compared to RF for RA. ACPA can divide patients with RA into two subgroups that differ in prognosis and response to treatment \[[@CR38], [@CR39]\] (Fig. [2](#Fig2){ref-type="fig"}). Patients with ACPA-positive RA differ from seronegative ones in genetics and environmental risk factors. The presence of ACPA is associated with genetic interaction between HLA-DRB1 shared epitope (SE) and PTPN22 risk allele \[[@CR40]\], and this points out how MHC class II-dependent T cell activation plays a central pathogenic role in the development of ACPA-positive RA. Furthermore, other gene interactions associated with ACPA-positive RA have been confirmed in several studies \[[@CR4], [@CR38]\]. ACPA are highly prevalent not only in patients with HLA-DRB1 SE, but also in those with HLA-DRB1\*15 non-SE, proposing that this latter allele can act as a second trigger that may intensify autoimmune response in predisposed subjects \[[@CR41]\]. Even gene--environment interaction can determine ACPA-positive RA, particularly in association with smoking and HLA-DRB1 SE, or with smoking and PTPN22 \[[@CR38]\]. It is interesting to note that SE and smoking are associated with the presence of all three autoantibodies specifically related with RA \[ACPA, RF and anti-carbamylated protein antibodies (anti-CarP)\] \[[@CR42]\].Fig. 2Features of ACPA-positive RA.Modified from Malmstrom et al. \[[@CR39], [@CR104]--[@CR114]\]

The influence of environmental factors, particularly smoking, has been shown to be a risk factor for the development of ACPA-positive RA; other environmental risk factors associated with ACPA are excessive coffee consumption, use of oral contraceptives and periodontitis caused by *Porphyromonas gingivalis*, while moderate alcohol consumption may be protective against this RA subtype \[[@CR43], [@CR44]\].

As previously discussed for ANA, also ACPA has a predictive role in autoimmune diseases, as well as RF and anti-RA-33 autoantibodies. In fact, they may occur early in the course of RA and are often present several years before the first symptoms \[[@CR45], [@CR46]\].

Numerous studies have shown that the presence of ACPA and their concentration are associated with the development of a more aggressive disease. Positive serum ACPA at baseline leads to a progressing and destructive form of RA, and they are the strongest independent predictor of radiographic damage \[[@CR47]--[@CR49]\]. ACPA have also been correlated with increased inflammation and extra-articular manifestations, high rates of disability and cardiovascular disease, with the latter most responsible for the premature mortality in RA \[[@CR38]\].

The distinction between ACPA-positive and ACPA-negative patients can also help us in the therapeutic choice; in fact, the superior efficacy of agents such as rituximab and abatacept in ACPA-positive patients has been demonstrated \[[@CR50], [@CR51]\]. This can occur because in these patients, the contribution of B cells to RA pathogenesis is more pronounced, and they might be more responsive to B cell-directed treatments than other patients \[[@CR52]\]. Also, methotrexate seems to be more effective in ACPA-positive subjects, in those patients in whom the arthritis stage is not fully defined by the ACR criteria, and it may delay the onset of RA \[[@CR38]\]. Conversely, ACPA positivity is correlated with a reduced response to all anti-tumor necrosis factor biologics \[[@CR53]\].

Rare autoantibodies {#Sec6}
-------------------

Rare autoantibodies characterize nearly all rheumatic diseases, despite not being included in any classification criteria set. Due to their low penetrance, they are not used as first-line test or generally available in routine laboratory, but they may help the clinician in making more accurate diagnoses and better management of patients, because they are associated with different disease manifestations and also with a greater incidence of cancer \[[@CR54]\]. This is particularly relevant for SSc, inflammatory myositis and SLE, for which we should note that the proposed clinical significance is derived from small cross-sectional studies.

The most significant autoantibodies in SSc are anti-centromere, anti-RNA polymerase III (anti-RNAP) and anti-Scl70, while anti-U3RNP is rarely found. Other autoantibodies are listed in Table [2](#Tab2){ref-type="table"} with their proposed clinical associations. Anti-RNAP antibodies are related to diffuse cutaneous SSc \[[@CR55]\], and they are the most consistent predictors of scleroderma renal crisis \[[@CR55]\]. It has also been shown that patients with anti-RNAP antibodies present more solid tumors and that these are temporally associated with the onset of SSc \[[@CR36], [@CR56]\]. Anti-Scl-70 antibodies are associated with a higher skin score, disease severity and activity \[[@CR57]\], and they are also strong predictors of the development of pulmonary fibrosis \[[@CR58], [@CR59]\], digital ulcers \[[@CR60]\] and malignancies \[[@CR61]\]. Finally, anti-U3RNP antibodies are strongly associated with muscle involvement and with an increased risk of pulmonary arterial hypertension \[[@CR59], [@CR62], [@CR63]\].Table 2Rare autoantibodies in systemic sclerosis and reported clinical associationsAutoantibodyPrevalence (%)Clinical associationsReferencesAnti-RNAP6--31dcSSc, renal crisis, malignancies\[[@CR85], [@CR86]\]Anti-Scl7010--40dcSSc, ILD, digital ulcers, cardiac involvement, malignancies\[[@CR87], [@CR88]\]Anti-U3RNP5--8dcSSc, cardiomyopathy, myopathy, PAH, ILD, severe small bowel involvement\[[@CR89]\]Anti-U1RNP4--14lcSSc, PAH, overlap syndrome\[[@CR90]\]Anti-Ku1--3Muscle and joint involvement\[[@CR91]\]Anti-PM-Scl2--10myositis, arthritis, lung or kidney involvement and mechanic's hands\[[@CR92]\]Anti-Th/To1--10lcSSc, PAH, ILD, puffy fingers, small bowel disease, hypothyroidism\[[@CR93]\]Anti-U11/U12RNP3ILD\[[@CR94]\]*dcSSc* diffuse systemic sclerosis, *lcSSc* limited systemic sclerosis, *PAH* pulmonary arterial hypertension, *PBC* primary biliary cholangitis, *ILD* interstitial lung disease

In the case of PM/DM, serum autoantibodies can be divided into myositis-specific antibodies (MSAs) (anti-Jo1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-Mi-2, anti-SRP, anti-KS, anti-TIF1γ/α (anti-155/140), anti-TIF1β, anti-MJ/NXP-2, anti-MDA5/CADM-140, anti-SAE) and myositis-associated antibodies (MAAs) (anti-PM-Scl, anti-Ku, anti-U1-RNP, anti-U1/U2-RNP, anti-U3-RNP) \[[@CR64]\]. The most noteworthy clinical associations are reported below, while others are reported in Table [3](#Tab3){ref-type="table"}. In general terms, rare autoantibodies in myositis are used to predict more severe forms, including those associated with cancer as many studies support the possibility that DM and PM are paraneoplastic, particularly DM \[[@CR65]\]. Some autoantibodies are associated with major recurrence of neoplasms, and these are anti-TIF1γ/α (anti-155-140) and anti NXP2 antibodies \[[@CR66], [@CR67]\]. Jo-1 and other anti-aminoacyl tRNA synthetases (anti-ARS) antibodies (PL-7, PL-12, EJ, OJ, KS) are associated with the so-called anti-synthetase syndrome, characterized by myositis, interstitial lung disease, arthritis, mechanic's hands and Raynaud's phenomenon \[[@CR68], [@CR69]\]. Anti-Mi-2 antibodies are related to DM with its typical skin manifestation, to good steroid response and good prognosis \[[@CR70]\]. Anti-SRP is specific for PM and correlates with a form of necrotizing myopathy, associated with a worse therapeutic response and poor prognosis \[[@CR64], [@CR71]\]. Rare autoantibodies detectable in SLE are listed in Table [4](#Tab4){ref-type="table"}; among these, anti-Sm antibodies are associated with lupus nephritis and neuropsychiatric complications, and renal disease association is stronger when they are found together with anti-dsDNA \[[@CR72]\]. These antibodies are also associated with discoid lupus and photosensitivity \[[@CR73]\]. Anti-ribosomal P antibodies are detected in the cerebrospinal fluid of patients with neuropsychiatric SLE \[[@CR74]\], indicating blood--brain barrier permeation, while they are also related to renal \[[@CR75]\] and hepatic damages \[[@CR76]\], malar rash, oral ulcers and photosensitivity \[[@CR77]\].Table 3Rare autoantibodies in myositis and reported clinical associations.Modified from Satoh et al. \[[@CR64]\]AutoantibodyPrevalence (%)Clinical associationsReferencesAnti-ARS1--30Anti-synthetase syndrome\[[@CR69], [@CR95]\]Anti-Mi210DM with typical skin lesions, mild disease\[[@CR69], [@CR70], [@CR95]\]Anti-TIF1γ10--15Severe DM, malignancies\[[@CR70], [@CR95]\]Anti-NPX21--5Severe DM, severe skin disease, malignancies\[[@CR69], [@CR70], [@CR95]\]Anti-MDA515--20CADM, ILD, severe skin manifestations, poor prognosis\[[@CR69], [@CR95], [@CR96]\]Anti-SAE1Amyopathic DM\[[@CR95]\]Anti-SRP5Necrotizing myopathy\[[@CR70]\]Anti-HMGCR6Necrotizing myopathy, proximal muscle weakness, elevated CK levels, prior statin use\[[@CR70], [@CR95], [@CR97]\]*Anti-ARS* anti-aminoacyl tRNA synthetases (Jo1, PL-7, PL-12, EJ, OJ, KS), *DM* dermatomyositis, *CADM* clinically amyopathic dermatomyositis, *ILD* interstitial lung disease, *CK* creatine kinase Table 4Rare autoantibodies in systemic lupus erythematosus and reported associationsAutoantibodyPrevalence (%)Clinical associationsReferencesAnti-Sm15LN, NPSLE, discoid SLE, photosensitivity\[[@CR98], [@CR99]\]Anti-ribosomal P10NPSLE, renal and hepatic disorders, malar rash, oral ulcer and photosensitivity, blood--brain barrier permeation\[[@CR77], [@CR98]\]Anti-La (SS-B)10--15Organ dysfunction (kidney, lung, liver)\[[@CR100], [@CR101]\]Anti-Ki6--20Hashimoto's thyroiditis, ITP, idiopathic ILD, PM/SSc overlap, synovitis, pericarditis, PAH, skin involvement and sicca symptoms\[[@CR102]\]Anti-histone21--81Drug-induced SLE\[[@CR103]\]*LN* lupus nephritis, *NPSLE* neuro psychiatric SLE, *SCLE* subacute cutaneous SLE, *UCTD* undifferentiated connective tissue disease, *ITP* autoimmune thrombocytopenia

Anti-drug antibodies (ADA) {#Sec7}
--------------------------

Since the introduction of biological drugs, the treatment of immune-mediated inflammatory diseases has witnessed an enormous improvement in the clinical armamentarium. Indeed, tumor necrosis factor α (TNF-α) inhibitors neutralizes the cytokine pro-inflammatory effect. Infliximab (IFX), adalimumab (ADL), golimumab (GOL), etanercept (ETA) and certolizumab (CTZ) can induce an immune response with the formation of autoantibodies against the drug, i.e., elicit immunogenicity, particularly after their prolonged use \[[@CR78], [@CR79]\].

ADA formation is caused by the recognition of drugs as non-self substances by the immune system. ADA ultimately act by causing the formation of complexes that block the binding between the drug and the target and also enhance the drug's clearance \[[@CR78]\]. Antibodies thus lead to a reduction in the serum levels of the drug to sub-therapeutic levels, resulting in loss of clinical efficacy \[[@CR79]\].

Therapeutic drug monitoring, done by measuring the TNF-α inhibitors serum levels and ADA, is considered an important factor for personalized TNF-α inhibitor treatment in chronic autoimmune diseases \[[@CR80]\]. Nevertheless, the mere presence of ADA does not directly correlate to drug loss of response and clinical consequences, since a significant amount of ADA is needed to neutralize much of the serum drug, which is usually given in high doses. More importantly, there is no agreement on the laboratory methods to be used for ADA detection in clinical practice. The significance of ADA largely depends on the quantity of antibodies produced and on the amount of drug not bound to them; if the quantity of ADA-free drug is substantial, the clinical impact will be minimal \[[@CR81]\]. Several studies have shown that ADA become detectable especially within the first year of treatment with TNF-α inhibitors, while their immunogenicity is very low after the first year of therapy \[[@CR82], [@CR83]\]. ADA levels are diminished using maintenance therapy rather than episodic therapy, since prolonged periods in which the drug is sub-dosed are avoided \[[@CR80]\]. Moreover, patients treated concomitantly with MTX have a lower risk of developing such antibodies, similarly to those responding to therapy \[[@CR78]\]. Overall, the determination of ADA levels and anti-TNF-α drug may be useful in patients where the clinical efficacy of TNF-α inhibitor has dropped. Pecoraro and colleagues suggest that in the presence of high ADA levels, either with optimal or suboptimal drug levels, the anti-TNF-α should be changed, while, in the case of low ADA levels, if drug levels are not adequate, the dosage or frequency of drug administration should be increased. Ultimately, however, the secondary loss of efficacy of an anti-TNF-α drug will lead to a treatment switch regardless of the mechanisms responsible for such loss. However others, in particular Steenholdt, suggest a different approach as shown in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3Proposed algorithm in patients with a rheumatic disease and anti-TNF-α treatment failure.Modified from Steenholdt et al. \[[@CR80]\]

Conclusions {#Sec8}
===========

The technological advances and a thorough knowledge of diseases pathogenesis over the last decade, combined with the increasing expectations of patients, have laid the foundation for developing an individualized management for a single patient, as opposed to that from the 'one size fits all' older school approach. The benefits of this approach have been discussed here, but they underline the numerous unmet needs in this field. In the case of serum autoantibodies, we cannot overlook the technological and methodological limitations that preclude (or prevent from) conclusive evidence. We would need more sensitive methods and experienced operators for the identification of rare antibodies and patterns. Moreover, most hospitals do not have laboratories with adequate machinery for rare autoantibodies or lack adequate standardization.

In general terms, the information derived from antibody positivity is of great help in setting up the most appropriate management, but it does not give us the assurance that the disease will be more severe, that the patients will develop organ involvement or even that they will develop malignancies. Because they are not specific tests for these manifestations, their positivity should act as a clue that draws our attention to such possible conditions. Their superficial interpretation could lead to excessive and useless diagnostic procedures and over-treatment, also causing unnecessary concern to the patient and his family.

These data, therefore, must be evaluated critically and integrated with the clinical history of the patient and with other laboratory data resulting in an a priori probability of having a specific disease. In an ancient Indian tale, several blind men seek to learn the nature of an elephant. One who examines the trunk describes the elephant to be like a snake. Another who feels one of the powerful legs states that the animal is similar to a tree trunk. The last, having touched the large elephant's ear, believes that this animal might be able to fly. Each blind man, focusing only on that part they were able to examine, missed entirely the true shape of the elephant. Understanding the individual components of the biological complexity of subjects is an important first step, but to better appreciate the "big picture," avoiding the mistake of those blind men is necessary to integrate all the information that comes from the patient as a unique individual, different from any other, so that the intent of personalized medicine can be realized.
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